HC Wainwright Analysts Decrease Earnings Estimates for CMPX

Compass Therapeutics, Inc. (NASDAQ:CMPX) – HC Wainwright dropped their Q3 2026 earnings estimates for shares of Compass Therapeutics in a report released on Thursday, August 6th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.15) for the quarter, down from their prior estimate of ($0.11). HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.56) EPS and FY2028 earnings at ($0.56) EPS.

Several other research firms have also weighed in on CMPX. Raymond James Financial lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. D. Boral Capital restated a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 27th. Wall Street Zen cut Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Finally, Stifel Nicolaus set a $6.00 price target on shares of Compass Therapeutics in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.77.

Compass Therapeutics Stock Up 3.3%

Shares of Compass Therapeutics stock opened at $2.22 on Monday. The stock has a market cap of $399.80 million, a PE ratio of -5.55 and a beta of 0.92. The business has a fifty day simple moving average of $2.09 and a 200-day simple moving average of $3.83. Compass Therapeutics has a 12 month low of $1.61 and a 12 month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02).

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its position in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the last quarter. Parallel Advisors LLC acquired a new position in Compass Therapeutics in the 1st quarter worth about $28,000. Creative Planning acquired a new position in Compass Therapeutics in the 2nd quarter worth about $30,000. State of Wyoming acquired a new position in Compass Therapeutics in the 2nd quarter worth about $31,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth about $32,000. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.